The CDC has authorized COVID-19 vaccine boosters for a limited number of patients at this time. The CDC has announced:
- People who are moderately to severely immunocompromised are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness.
- People who have compromised immune systems may benefit from an additional dose to make sure they have enough protection against COVID-19.
- CDC recommends people who are moderately to severely immunocompromised should receive an additional dose of mRNA COVID-19 vaccine after the initial 2 doses.
CDC recommends that people with moderately to severely compromised immune systems receive an additional dose of mRNA COVID-19 vaccine at least 28 days after a second dose of Pfizer-BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine.
CDC does not recommend additional doses or booster shots for any other population at this time.
Patients with asthma, eczema, and allergic diseases, including patients taking biologic medications such as Xolair, Nucala, Fasenra, or Dupixent, are not candidates for the booster at this time, unless they have another reason to be immunocompromised. Patients on certain other biologics including Humira and treatments for arthritis, psoriasis, and other conditions may be candidates, and should speak with their primary care physician. Patients with immunodeficiency illnesses such as common variable immunodeficiency may also be candidates, and should speak with their managing physician.